Abstract
Among patients with non-small cell lung cancer (NSCLC), EGFR mutations, 90% of which present as an exon 19 deletion or exon 21 point mutation L858R, have been detected in Western and Asian populations at a rate of ~15% and ~40%, respectively. To date, numerous trials have established the efficacy and toxicity profile of singleagent oral EGFR-tyrosine kinase inhibitor (TKI) therapies for EGFR-TKI-naive NSCLC patients harboring EGFR mutations. These trials include IPASS for gefitinib (1), Optimal for erlotinib (2), and LUX-Lung 3 for afatinib (3). Still, the majority of patients will eventually develop resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
